Skip to content

Implementing a Digital Alcohol Intervention to Raise Women's Awareness of Alcohol-related Breast Cancer Risk During Routine Screening Visits

Implementing a Digital Alcohol Intervention to Raise Women's Awareness of Alcohol-related Breast Cancer Risk During Routine Screening Visits

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07799467
Enrollment
36
Registered
2026-09-02
Start date
2026-10-15
Completion date
2027-03-01
Last updated
2026-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Drinking, Breast Cancer

Brief summary

This study is a single-arm feasibility trial evaluating a digital behavioral intervention designed to increase women's awareness of the relationship between alcohol use and breast cancer risk during routine breast cancer screening visits. The study will enroll 36 women aged 40 years or older. Participants will complete baseline measures and receive the Sobriety digital intervention during the clinic visit, followed by 4 weeks of continued access to the platform. Assessments will be completed immediately after the intervention and at 3 months to evaluate feasibility, acceptability, engagement, and changes in alcohol-related knowledge and behavior.

Interventions

BEHAVIORALSobriety Digital Intervention

Participants will receive a digital behavioral intervention that includes alcohol use screening, personalized feedback, education on alcohol-related breast cancer risk, brief motivational content, and goal-setting exercises. Participants will retain access to the intervention platform for 4 weeks following the initial intervention.

Sponsors

University of Miami
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women attending their screening visit * Regular alcohol users * Aged 40+ years * Fluent in English * With or without cancer * Not currently receiving cancer treatment * Own a smartphone, iPad, or computer * Able to provide consent * Must not have participated in Stage 1 or Stage 2.

Exclusion criteria

* Younger than 40 years * Non-English speaking * Unable to provide informed consent * Does not own a smartphone, iPad, or computer * Currently receiving cancer treatment * Prior participation in Stage 1 or Stage 2.

Design outcomes

Primary

MeasureTime frameDescription
Recruitment RateDuring the recruitment periodPercentage of eligible participants approached for participation who provide informed consent and enroll in the study. Recruitment feasibility will be considered achieved if at least 70% of eligible participants approached enroll in the study.
Retention Rate3-month follow-upPercentage of enrolled participants who complete the 3-month follow-up assessment. Retention feasibility will be considered achieved if at least 75% of enrolled participants complete the 3-month follow-up assessment.
Intervention CompletionOver the 3-month intervention periodPercentage of enrolled participants who complete all core intervention modules. Intervention feasibility will be considered achieved if at least 70% of enrolled participants complete the core intervention modules.
System Usability Scale (SUS) Score3-month follow-upParticipant-reported usability of the intervention as assessed using the System Usability Scale (SUS), a 10-item questionnaire with total scores ranging from 0 to 100. Higher scores indicate greater perceived usability. Acceptability will be considered satisfactory if the mean SUS score is at least 70.
Participants Rating the Intervention as Helpful or Very Helpful3-month follow-upPercentage of participants who rate the intervention as "helpful" or "very helpful" on a participant satisfaction assessment. Acceptability will be considered satisfactory if at least 80% of participants rate the intervention as helpful or very helpful.

Countries

United States

Contacts

CONTACTTaghrid Asfar, MD,MSPH
tasfar@med.miami.edu305-243-3826
CONTACTMaria Fernanda Garcia, BS
mfg136@miami.edu561-569-7987
PRINCIPAL_INVESTIGATORTaghrid Asfar, MD,MSPH

University of Miami

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 3, 2026